Premium
ANI Pharmaceuticals Inc (ANIP)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Mr. Patrick D. WalshInitié | -13,97k | 1,13M | Vente | 80,63 - 80,75 | 38,43k | -26,66% |
| 2026-05-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -459,00 | 36,36k | Vente | 79,21 | 38,27k | -1,19% |
| 2026-05-12 | Mr. Ori GutwergSVP of Generics | -2,77k | 220,37k | Vente | 79,50 | 78,70k | -3,40% |
| 2026-05-11 | Mr. Nikhil LalwaniPresident, CEO & Director | -55,00k | 4,27M | Vente | 77,57 | 349,89k | -13,58% |
| 2026-05-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 39,08k | Automatic Disposition | 78,16 | 78,39k | -0,63% |
| 2026-04-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 38,98k | Automatic Disposition | 77,95 | 78,89k | -0,63% |
| 2026-03-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 36,31k | Automatic Disposition | 72,62 | 79,39k | -0,63% |
| 2026-03-11 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -4,77k | 357,47k | Vente | 74,91 | 38,73k | -10,97% |
| 2026-03-13 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -3,16k | 226,53k | Automatic Disposition | 71,64 | 91,31k | -3,35% |
| 2026-03-06 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,72k | 424,62k | Automatic Disposition | 74,18 - 74,22 | 94,47k | -5,71% |
| 2026-03-07 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -3,31k | 245,37k | Sale to Issuer | 74,04 | 94,47k | -3,39% |
| 2026-03-07 | Mr. Nikhil LalwaniPresident, CEO & Director | -17,06k | 1,26M | Sale to Issuer | 74,04 | 404,89k | -4,04% |
| 2026-03-07 | Mr. Ori GutwergSVP of Generics | -3,31k | 245,37k | Sale to Issuer | 74,04 | 81,47k | -3,91% |
| 2026-03-06 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -6,57k | 488,47k | Automatic Disposition | 74,13 - 75,00 | 51,95k | -11,23% |
| 2026-03-07 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,15k | 381,31k | Sale to Issuer | 74,04 | 180,39k | -2,78% |
| 2026-03-05 | Mr. Stephen P. CareySenior VP of Finance & CFO | -3,31k | 85,81k | Derivative Exercise and Sale | 49,51 - 75,42 | 185,54k | - |
| 2026-03-05 | Mr. Stephen P. CareySenior VP of Finance & CFO | -4,00k | 302,24k | Vente | 75,56 | 185,54k | -2,11% |
| 2026-03-02 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -417,00 | 30,86k | Automatic Disposition | 74,00 | 103,51k | -0,40% |
| 2026-03-03 | Mr. Ori GutwergSVP of Generics | -2,06k | 157,59k | Vente | 76,50 | 84,78k | -2,37% |
| 2026-03-03 | Mr. Patrick D. WalshInitié | -6,00k | 445,38k | Vente | 74,23 | 52,41k | -10,27% |
| 2026-02-28 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -628,00 | 46,41k | Sale to Issuer | 73,90 | 43,50k | -1,42% |
| 2026-02-28 | Mr. Nikhil LalwaniPresident, CEO & Director | -12,22k | 902,84k | Sale to Issuer | 73,90 | 421,95k | -2,81% |
| 2026-02-28 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -2,22k | 164,13k | Sale to Issuer | 73,90 | 103,93k | -2,09% |
| 2026-02-28 | Mr. Ori GutwergSVP of Generics | -2,22k | 164,13k | Sale to Issuer | 73,90 | 86,84k | -2,49% |
| 2026-02-28 | Mr. Stephen P. CareySenior VP of Finance & CFO | -2,77k | 204,92k | Sale to Issuer | 73,90 | 189,54k | -1,44% |
| 2026-02-28 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -1,56k | 114,91k | Sale to Issuer | 73,90 | 79,89k | -1,91% |
| 2026-02-28 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,56k | 114,91k | Sale to Issuer | 73,90 | 58,52k | -2,59% |
| 2026-02-28 | Mr. Chad GassertSVP of Corporate Development & Strategy | -2,22k | 164,13k | Sale to Issuer | 73,90 | 233,41k | -0,94% |
| 2026-02-19 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -3,81k | 296,50k | Automatic Disposition | 77,53 - 77,99 | 49,26k | -7,19% |
| 2026-02-20 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,32k | 415,30k | Automatic Disposition | 78,02 | 84,84k | -5,90% |
| 2026-02-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -1,05k | 80,93k | Sale to Issuer | 76,70 - 77,36 | 38,11k | -2,68% |
| 2026-02-12 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -7,03k | 538,30k | Automatic Disposition | 76,55 | 90,16k | -7,23% |
| 2026-02-12 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -5,58k | 429,27k | Sale to Issuer | 76,70 - 77,36 | 90,16k | -5,82% |
| 2026-02-12 | Mr. Nikhil LalwaniPresident, CEO & Director | -21,99k | 1,69M | Sale to Issuer | 76,70 - 77,36 | 358,57k | -5,78% |
| 2026-02-12 | Mr. Ori GutwergSVP of Generics | -3,66k | 282,20k | Sale to Issuer | 76,70 - 77,36 | 76,09k | -4,59% |
| 2026-02-12 | Mr. Chad GassertSVP of Corporate Development & Strategy | -3,33k | 256,16k | Sale to Issuer | 76,70 - 77,36 | 224,51k | -1,46% |
| 2026-02-12 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -2,47k | 190,30k | Sale to Issuer | 76,70 - 77,36 | 53,08k | -4,45% |
| 2026-02-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 38,40k | Automatic Disposition | 76,80 | 67,55k | -0,73% |
| 2026-02-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -3,31k | 255,28k | Sale to Issuer | 76,70 - 77,36 | 67,55k | -4,68% |
| 2026-02-12 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,28k | 406,36k | Sale to Issuer | 76,70 - 77,36 | 170,08k | -3,01% |
| 2026-02-11 | Mr. Stephen P. CareySenior VP of Finance & CFO | -5,50k | 419,60k | Sale to Issuer | 76,25 | 175,36k | -3,04% |
| 2026-02-11 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -3,01k | 229,59k | Sale to Issuer | 76,25 | 71,36k | -4,05% |
| 2026-02-11 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -3,02k | 230,05k | Sale to Issuer | 76,25 | 55,55k | -5,15% |
| 2026-02-11 | Mr. Chad GassertSVP of Corporate Development & Strategy | -4,27k | 325,51k | Sale to Issuer | 76,25 | 227,84k | -1,84% |
| 2026-02-11 | Mr. Ori GutwergSVP of Generics | -4,27k | 325,36k | Sale to Issuer | 76,25 | 79,76k | -5,08% |
| 2026-02-11 | Mr. Nikhil LalwaniPresident, CEO & Director | -30,66k | 2,34M | Sale to Issuer | 76,25 | 380,56k | -7,46% |
| 2026-02-11 | Mr. Christopher K. MutzSenior Vp & Head of Rare Disease | -4,55k | 346,63k | Sale to Issuer | 76,25 | 102,77k | -4,24% |
| 2026-02-11 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -1,76k | 134,35k | Sale to Issuer | 76,25 | 39,16k | -4,31% |
| 2026-02-11 | Mr. Muthusamy ShanmugamHead of R&D, COO of New Jersey Operations & Director | -2,90k | 220,97k | Sale to Issuer | 76,25 | 71,42k | -3,90% |
| 2026-01-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -500,00 | 42,17k | Automatic Disposition | 84,33 | 74,37k | -0,67% |
| 2025-12-18 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,62k | 133,65k | Automatic Disposition | 82,40 | 58,56k | -2,69% |
| 2025-12-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 32,93k | Automatic Disposition | 82,32 | 74,87k | -0,53% |
| 2025-12-05 | Dr. Renee P. TannenbaumIndependent Director | -1,80k | 146,07k | Vente | 81,15 | 25,16k | -6,68% |
| 2025-11-13 | Mr. Patrick D. WalshInitié | -8,64k | 750,90k | Vente | 86,88 | 58,41k | -12,89% |
| 2025-11-13 | Mr. Patrick D. WalshInitié | -3,00k | 0,00 | Other Disposition | - | 58,41k | -4,89% |
| 2025-11-12 | Mr. Chad GassertSVP of Corporate Development & Strategy | -14,64k | 1,30M | Vente | 89,07 | 232,11k | -5,93% |
| 2025-11-13 | Mr. Chad GassertSVP of Corporate Development & Strategy | -94,00 | 8,27k | Vente | 88,00 | 232,11k | -0,04% |
| 2025-11-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 34,91k | Automatic Disposition | 87,27 | 75,27k | -0,53% |
| 2025-10-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 36,04k | Automatic Disposition | 90,09 | 75,67k | -0,53% |
| 2025-09-19 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1 000,00 | 98,04k | Automatic Disposition | 98,04 | 60,19k | -1,63% |
| 2025-09-12 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 39,37k | Automatic Disposition | 98,42 | 76,07k | -0,52% |
| 2025-09-12 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,71k | 167,08k | Sale to Issuer | 97,71 | 61,19k | -2,72% |
| 2025-09-03 | Mr. Antonio R. PeraIndependent Director | -7,29k | 692,30k | Vente | 94,94 | 22,66k | -24,35% |
| 2025-08-25 | Mr. Matthew J. LeonardIndependent Director | -2,53k | 229,09k | Vente | 90,62 | 6,86k | -26,92% |
| 2025-08-22 | Ms. Krista L. DavisSenior VP & Chief HR Officer | -1,76k | 160,61k | Vente | 91,10 | 62,90k | -2,73% |
| 2025-08-20 | Esjay LlcSociété | -100,00k | 9,04M | Vente | 90,27 - 90,44 | 431,92k | -18,80% |
| 2025-08-20 | Mr. Antonio R. PeraIndependent Director | -5,42k | 486,43k | Vente | 89,73 | 29,95k | -15,33% |
| 2025-08-18 | Ms. Jeanne A. ThomaIndependent Director | -21,54k | 1,92M | Vente | 88,87 - 89,76 | 23,41k | -47,93% |
| 2025-08-18 | Mr. Matthew J. LeonardIndependent Director | -6,94k | 611,64k | Vente | 88,17 | 9,39k | -42,48% |
| 2025-08-15 | Mr. Patrick D. WalshInitié | -9,00k | 801,45k | Vente | 89,05 | 70,05k | -11,39% |
| 2025-08-14 | Esjay LlcSociété | -100,00k | 8,82M | Vente | 87,15 - 89,48 | 531,92k | -15,82% |
| 2025-08-15 | Mr. Chad GassertSVP of Corporate Development & Strategy | -20,00k | 1,74M | Vente | 86,97 | 246,84k | -7,50% |
| 2025-08-12 | Mr. Thomas Andrew RowlandSenior VP & Head of Established Brands | -4,98k | 426,41k | Vente | 85,71 | 40,79k | -10,87% |
| 2025-08-12 | Mr. Nikhil LalwaniPresident, CEO & Director | -56,96k | 4,89M | Vente | 85,93 | 411,22k | -12,17% |
| 2025-08-12 | Mr. Ori GutwergSVP of Generics | -5,87k | 508,19k | Vente | 86,53 | 84,02k | -6,53% |
| 2025-08-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 35,55k | Automatic Disposition | 88,87 | 76,47k | -0,52% |
| 2025-08-12 | Mr. Stephen P. CareySenior VP of Finance & CFO | -50,00k | 1,98M | Derivative Exercise and Sale | 46,49 - 86,07 | 180,86k | - |
| 2025-08-12 | Mr. Thomas J. HaugheyIndependent Chairman of the Board | -19,34k | 1,66M | Vente | 85,93 | 36,52k | -34,62% |
| 2025-07-18 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -2,07k | 137,31k | Sale to Issuer | 66,30 | 76,87k | -2,62% |
| 2025-07-14 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 25,95k | Automatic Disposition | 64,88 | 78,95k | -0,50% |
| 2025-06-13 | Ms. Meredith W. CookSenior VP, General Counsel & Corporate Secretary | -400,00 | 24,55k | Automatic Disposition | 61,37 | 79,35k | -0,50% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
